These findings indicate that PTEN mutations are relatively common in NSCLC, and thus analysis of PTEN mutations may facilitate a comprehensive understanding of the genetic alterations related to the EGFR signaling pathway. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.